5 mg or 25 mg psilocybin with psychological support for generalized anxiety
About this title
A Phase IIb multicentre, randomised, double-blind, two-arm trial comparing the efficacy and safety of 25 mg psilocybin plus psychological support versus 5 mg psilocybin plus psychological support in adults with severe generalized anxiety disorder (GAD) (PSiGAD2)
Read the official source — ISRCTN14487299Understand this study
Who could participate?
This study is for people with anxiety. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.
- Listed locations
- United Kingdom
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Incannex Healthcare Limited
- Sponsor type
- Unknown or unclear
- Study type
- Other
- Intervention type
- Other / unclear
- Locations
- United Kingdom
- Age range
- From 18 Years to 70 Years
- Official registry ID
- ISRCTN14487299
- Official title
Show the full official title
A clinical trial of 5 mg psilocybin plus psychological support vs 25 mg psilocybin plus psychological support in adults with generalised anxiety disorder
Recruitment & locations
United Kingdom
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Incannex Healthcare Limited.
Who can participate?
This study is for people with anxiety. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
